| Completed | Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does T NCT06919627 | University Hospital, Brest | — |
| Not Yet Recruiting | DNA Methylation and the Increased Risk of Cervical Cancer Development NCT06859151 | Zhujiang Hospital | — |
| Recruiting | HPV Self-sampling for Women Who do Not Attend Cervical Cancer Screening Programme NCT06371118 | Universidade do Porto | N/A |
| Active Not Recruiting | Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) NCT05797246 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 NCT05580341 | Shanghai Zerun Biotechnology Co.,Ltd | Phase 3 |
| Active Not Recruiting | V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071) NCT05450705 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribon NCT05119855 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052) NCT05285826 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Intervention for Human Papillomavirus Vaccine Acceptance in Mexican Mothers NCT06854354 | Hospital Univeristario Benemerita Universidad Autonoma de Puebla | N/A |
| Completed | Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR). NCT06399341 | Elpen Pharmaceutical Co. Inc. | — |
| Unknown | Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infec NCT04910438 | ANRS, Emerging Infectious Diseases | — |
| Completed | ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection NCT06439433 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V50 NCT04772534 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis NCT04724980 | Precigen, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-0 NCT04708041 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | Changes in the Prevalence of Oncogenic HPV Types NCT04671823 | Kanazawa Medical University | — |
| Completed | HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study NCT04694495 | Zhujiang Hospital | — |
| Terminated | E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer NCT04015336 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vac NCT04199689 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN NCT04115787 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | — |
| Completed | Integrated Cervical Cancer Screening in Mayuge District Uganda (ASPIRE Mayuge) NCT04000503 | University of British Columbia | N/A |
| Withdrawn | A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I NCT04044950 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) NCT03998254 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts NCT03981822 | Verrica Pharmaceuticals Inc. | Phase 2 |
| Completed | Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years NCT03903562 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma NCT04124198 | Christian von Buchwald | N/A |
| Completed | A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects NCT03929172 | 2A Pharma AB | Phase 1 |
| Unknown | The KEN SHE Study on HPV-vaccine Efficacy NCT03675256 | Massachusetts General Hospital | Phase 4 |
| Unknown | Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection NCT03548740 | Peking Union Medical College Hospital | — |
| Completed | Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females NCT03546842 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Cantharidin and Occlusion in Verruca Epithelium NCT03487549 | Verrica Pharmaceuticals Inc. | Phase 2 |
| Completed | E7 TCR T Cells for Human Papillomavirus-Associated Cancers NCT02858310 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination NCT02897232 | Louisiana State University Health Sciences Center Shreveport | — |
| Completed | Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) NCT02631863 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV) NCT02535104 | Tamir Biotechnology, Inc. | Phase 1 / Phase 2 |
| Completed | Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal NCT03584308 | Catalysis SL | Phase 2 |
| Completed | Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix NCT02346227 | Jean-Pierre Van geertruyden | Phase 3 |
| Completed | Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation NCT01894425 | Centre Hospitalier Universitaire de Nīmes | — |
| Completed | Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment NCT06700941 | Universidad Nacional de Colombia | — |
| Completed | GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) NCT01245764 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM) NCT01295242 | University of Washington | — |
| Completed | A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V NCT01254643 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | PApillomavirus in REnal Transplant Patient NCT02845739 | Centre Hospitalier Universitaire de Besancon | N/A |
| Completed | A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007) NCT01073293 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Self-collected Swabs for HPV Testing in 18-24 Year Old Women NCT01101828 | University of Washington | — |
| Completed | Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands NCT00973856 | Cleveland Clinic Akron General | N/A |
| Unknown | Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV NCT01709448 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED) NCT00496626 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | HPV Infections in Older Women NCT00743392 | University of Washington | — |
| Completed | Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 NCT00685412 | Inovio Pharmaceuticals | Phase 1 |
| Terminated | GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077) NCT01355003 | Merck Sharp & Dohme LLC | — |
| Completed | Human Papillomavirus 6/11 in the Lower Airway of Neonates NCT00549250 | National Taiwan University Hospital | — |
| Completed | Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix NCT04072913 | University Hospital, Bordeaux | N/A |
| Withdrawn | Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities NCT00501189 | Eisenhower Army Medical Center | — |
| Completed | Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Year NCT00380367 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | High-Risk HPV Infections in Women Aged 25 to 65 NCT00461877 | University of Washington | — |
| Terminated | Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. NCT00117884 | Takeda | Phase 2 |
| Terminated | Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. NCT00312286 | Takeda | Phase 2 |
| Unknown | Oral Human Papillomavirus Infection in HIV-infected Men NCT00421486 | Deutsche Luft und Raumfahrt | — |
| Completed | Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) NCT00157950 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Human Papillomavirus (HPV) Infection in Pregnancy NCT00194311 | University of Pennsylvania | — |
| Completed | A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) NCT00092547 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men NCT00365729 | Deutsche Luft und Raumfahrt | — |
| Unknown | Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and t NCT00124878 | Wawer, Maria J., M.D. | Phase 3 |
| Completed | Screening for HIV-Associated Anal Cancer NCT00188292 | University Health Network, Toronto | — |
| Completed | Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) NCT00365716 | Merck Sharp & Dohme LLC | Phase 2 |